Sanctuary Advisors LLC Grows Stock Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Sanctuary Advisors LLC grew its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 91.8% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 4,558 shares of the biopharmaceutical company’s stock after purchasing an additional 2,181 shares during the period. Sanctuary Advisors LLC’s holdings in Alnylam Pharmaceuticals were worth $1,254,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also made changes to their positions in ALNY. Eventide Asset Management LLC boosted its stake in Alnylam Pharmaceuticals by 157.9% during the third quarter. Eventide Asset Management LLC now owns 224,333 shares of the biopharmaceutical company’s stock worth $61,698,000 after buying an additional 137,333 shares during the last quarter. Los Angeles Capital Management LLC boosted its position in shares of Alnylam Pharmaceuticals by 11,433.4% during the 3rd quarter. Los Angeles Capital Management LLC now owns 137,017 shares of the biopharmaceutical company’s stock valued at $37,684,000 after acquiring an additional 135,829 shares during the last quarter. AQR Capital Management LLC grew its holdings in shares of Alnylam Pharmaceuticals by 92.5% in the second quarter. AQR Capital Management LLC now owns 271,619 shares of the biopharmaceutical company’s stock valued at $65,862,000 after purchasing an additional 130,482 shares during the period. Deerfield Management Company L.P. Series C acquired a new stake in Alnylam Pharmaceuticals during the second quarter worth about $29,111,000. Finally, Avoro Capital Advisors LLC raised its stake in Alnylam Pharmaceuticals by 33.3% during the second quarter. Avoro Capital Advisors LLC now owns 400,000 shares of the biopharmaceutical company’s stock worth $97,200,000 after purchasing an additional 100,000 shares during the period. 92.97% of the stock is currently owned by hedge funds and other institutional investors.

Alnylam Pharmaceuticals Stock Up 2.8 %

Alnylam Pharmaceuticals stock opened at $245.44 on Friday. The firm has a market capitalization of $31.66 billion, a P/E ratio of -93.68 and a beta of 0.32. The company has a current ratio of 2.75, a quick ratio of 2.69 and a debt-to-equity ratio of 31.64. Alnylam Pharmaceuticals, Inc. has a twelve month low of $141.98 and a twelve month high of $304.39. The stock’s fifty day simple moving average is $264.61 and its 200-day simple moving average is $250.74.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.36). The business had revenue of $500.90 million during the quarter, compared to the consensus estimate of $532.91 million. Alnylam Pharmaceuticals’s revenue for the quarter was down 33.3% compared to the same quarter last year. During the same quarter last year, the business posted $1.15 EPS. As a group, equities analysts expect that Alnylam Pharmaceuticals, Inc. will post -2.21 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

ALNY has been the subject of several analyst reports. William Blair reissued an “outperform” rating on shares of Alnylam Pharmaceuticals in a research note on Tuesday, November 19th. JPMorgan Chase & Co. upped their price objective on Alnylam Pharmaceuticals from $248.00 to $280.00 and gave the company a “neutral” rating in a report on Monday, August 26th. Scotiabank raised their target price on Alnylam Pharmaceuticals from $305.00 to $310.00 and gave the stock a “sector outperform” rating in a research note on Friday, November 1st. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $300.00 price target on shares of Alnylam Pharmaceuticals in a research note on Friday, November 1st. Finally, Barclays increased their price target on Alnylam Pharmaceuticals from $295.00 to $329.00 and gave the stock an “overweight” rating in a report on Friday, November 1st. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and nineteen have given a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $298.09.

Insider Buying and Selling

In related news, CMO Pushkal Garg sold 1,752 shares of the business’s stock in a transaction on Thursday, December 12th. The shares were sold at an average price of $251.00, for a total transaction of $439,752.00. Following the completion of the transaction, the chief marketing officer now owns 15,705 shares in the company, valued at approximately $3,941,955. The trade was a 10.04 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Yvonne Greenstreet sold 5,219 shares of the firm’s stock in a transaction on Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total value of $1,309,864.62. Following the completion of the sale, the chief executive officer now owns 78,880 shares in the company, valued at approximately $19,797,302.40. This represents a 6.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 10,122 shares of company stock worth $2,540,455. Company insiders own 1.50% of the company’s stock.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.